real-world registry

French Registry Data Show Marked Declines in Relapse Activity and Faster Diagnosis in AQP4+NMOSD and MOGAD From 2010 to 2024

A nationwide French cohort found earlier diagnosis, falling relapse rates, and major treatment shifts in AQP4+NMOSD and MOGAD, with rituximab linked to lower disability risk in AQP4+NMOSD and overall milder disability trajectories in MOGAD.

Real-World Insights into Clinical Presentation and Outcomes After Mitral Valve Surgery from the MITRACURE Registry